Alunbrig (brigatinib) — Medica
Peripheral T-Cell Lymphomas – ALK-positive anaplastic large cell lymphoma (ALCL)
Initial criteria
- Patient is age ≥ 18 years
- Patient has anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
Approval duration
1 year